WebParticularly significant evidence supporting chitosan as an adjuvant for nasal vaccination comes from clinical investigations on a norovirus vaccine; this demonstrated the ability of …
Archimedes Pharma Acquires Chitosan Intellectual Property ... - BioSpace
WebMay 4, 2006 · The contribution of ChiSys(TM) to enhancing mucosal drug absorption reflects several factors including its potent mucoadhesive property, which prevents drug washout. Rylomine(TM) is a novel formulation of morphine and ChiSys(TM) packaged in a single 7.5 mg unit nasal spray. Worldwide, no comparable formulation of morphine is … WebSep 8, 2009 · ChiSys, an innovative drug delivery technology which enhances the residence time of molecules on mucosal membranes, has proven potential for vaccine delivery. Pre-clinical and clinical studies of nasally administered vaccines have demonstrated enhanced immune response. PecSys™ is Archimedes’ patented drug delivery system built around … taxable income after full retirement age
An intranasal vaccine targeting both the Bacillus anthracis toxin …
WebSep 3, 2024 · ChiSys commented Sep 19, 2024 • edited Highest working res (with all effects working) in WoFF is 864x480(=414720 rendered pixels). 960x416(=399360) are more than 800x480(=384000) but lower than 864x480. WebMay 1, 2006 · Rabbits were vaccinated intranasally with PA-based vaccines formulated as dry powders with or without chitosan (ChiSys, Archimedes Development Limited), a compound that exhibits muco-adhesive properties, or as a liquid. Formulations also contained MPL adjuvant and PA. Some vaccines contained PA conjugated to a 10-mer … WebSep 15, 2008 · The intellectual property acquired will allow Archimedes to significantly extend the applicability of ChiSys®, Archimedes' highly effective proprietary chitosan … taxable income and net income